76 terminated. 76 Phase 2, 12 Phase 3, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 76 | Terminated 76 |
| Phase 3 | 12 | Terminated 12 |
| Phase 1 | 7 | Terminated 7 |
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients Ketamine Hydrochloride, Placebo - Depression | Phase 2 | Terminated | Mayo Clinic | 1 | 2025-07-07 | 2026-08-12 |
| SAINT for MDD in an Inpatient Setting Follow-on Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| Ketamine for OUD and Suicidal Ideation in the ED Ketamine, Saline Solution - Opioid Use Disorder, Suicidal Ideation | Phase 2 | Terminated | Brigham and Women's Hospital | 4 | 2024-06-14 | 2025-04-08 |
| Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality Transdermal Estradiol, Placebo - Suicide | Phase 2 | Terminated | University of Illinois at Chicago | 11 | 2024-03-16 | 2025-10-29 |
| Role of CBD in Improving Alexithymia Purysis CBD, Placebo - Alexithymia, HIV | Phase 2 | Terminated | University of California, San Diego | 6 | 2024-03-12 | 2026-09-01 |
| Phase 2 Clinical Trial of GH001 in Bipolar II Disorder GH001 - Bipolar II Disorder | Phase 2 | Terminated | GH Research Ireland Limited | 6 | 2023-04-06 | 2025-02-18 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| Phase 2 Clinical Trial of GH001 in Postpartum Depression GH001 - Postpartum Depression, Postnatal Depression | Phase 2 | Terminated | GH Research Ireland Limited | 10 | 2023-03-02 | 2025-02-18 |
| INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD INP105, Placebo - Agitation in Adolescents and Young Adults With ASD | Phase 2 | Terminated | Impel Pharmaceuticals | 8 | 2022-06-23 | 2023-09-28 |
| Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics Ketamine Injectable Solution, Midazolam Injectable Solution, Normal Saline 0.9% Injectable Solution - Suicidal Ideation | Phase 1 / Phase 2 | Terminated | University of British Columbia | 15 | 2022-06-01 | 2024-12-18 |
| A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic OTX-202, OTX-000, Treatment as Usual - Suicide, Attempted, Suicidal Ideation | Phase 2 / Phase 3 | Terminated | Oui Therapeutics, Inc. | 356 | 2022-04-07 | 2025-06-12 |
| An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia BXCL501, Placebo film - Agitation, Dementia | Phase 2 | Terminated | BioXcel Therapeutics Inc | 5 | 2022-02-08 | 2026-08-11 |
| Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent MIJ821 Intravenous Injection, Placebo Intravenous Injection - Major Depressive Disorder With Suicidal Ideation With Intent | Phase 2 | Terminated | Novartis Pharmaceuticals | 199 | 2021-07-20 | 2026-05-18 |
| Antidepressant Effects of TS-161 in Treatment-Resistant Depression Placebo, TS-161 - Major Depressive Disorder, Treatment-Resistant Depression | Phase 2 | Terminated | National Institute of Mental Health (NIMH) | 11 | 2021-06-10 | 2025-06-10 |
| Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) AXS-05 (dextromethorphan-bupropion) - Treatment Resistant Depression, Major Depressive Disorder | Phase 2 | Terminated | Axsome Therapeutics, Inc. | 181 | 2020-09-23 | 2026-01-28 |
| Tofacitinib in Depression (TIDE) Tofacitinib 5 MG [Xeljanz], Placebo - Depression, Inflammation | Phase 1 / Phase 2 | Terminated | University of Oxford | 2 | 2020-02-10 | 2022-08-09 |
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy Ketamine infusion, Midazolam infusion - Major Depressive Disorder | Phase 2 / Phase 3 | Terminated | Yale University | 3 | 2019-07-17 | 2023-04-24 |
| Salicylic Augmentation in Depression Aspirin 325mg, Placebo Oral Tablet - Depression, Depressive Disorder | Phase 2 | Terminated | Jessica Harder | 32 | 2018-11-15 | 2024-01-31 |
| Ketamine in Borderline Personality Disorder Ketamine, Midazolam - Borderline Personality Disorder | Phase 2 | Terminated | Yale University | 22 | 2018-02-15 | 2023-06-26 |
Showing 20 of 76. Sign in to see all of them.
Depression (58) · Depressive Disorder, Major (24) · Bipolar Disorder (11) · Depressive Disorder (7) · Psychomotor Agitation (7) · Depressive Disorder, Treatment-Resistant (6) · Suicidal Ideation (6) · Anxiety Disorders (4) · Mood Disorders (4) · Suicide (4) · Borderline Personality Disorder (3) · Dementia (3) · Self-Injurious Behavior (3) · Aggression (2) · Alzheimer Disease (2)
Behavior (76) · Mental Disorders (53) · Mood Disorders (34) · Depressive Disorder (23) · Nervous System Diseases (18) · Pathological Conditions, Signs and Symptoms (18) · Signs and Symptoms (14) · Bipolar and Related Disorders (11) · Neurologic Manifestations (11) · Brain Diseases (10) · Central Nervous System Diseases (10) · Neurobehavioral Manifestations (9) · Dyskinesias (8) · Self-Injurious Behavior (8)
Ketamine (7) · Escitalopram (3) · Duloxetine Hydrochloride (2) · Melatonin (2) · Methoxydimethyltryptamines (2) · Quetiapine Fumarate (2) · Saline Solution (2) · Scopolamine (2) · Sertraline (2) · Sugars (2) · orvepitant (2) · 1-(benzofurazan-5-ylcarbonyl)piperidine (1) · 6-(2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine (1) · AZD2066 (1) · Acetylcysteine (1)
National Institute of Mental Health (NIMH) (7) · H. Lundbeck A/S (3) · Janssen Research & Development, LLC (3) · Massachusetts General Hospital (3) · Yale University (3) · Brigham and Women's Hospital (2) · GH Research Ireland Limited (2) · GlaxoSmithKline (2) · Magnus Medical (2) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · University of Cincinnati (2) · University of Texas Southwestern Medical Center (2) · ACADIA Pharmaceuticals Inc. (1) · AstraZeneca (1)
United States (57) · Canada (12) · United Kingdom (7) · Netherlands (6) · Germany (5) · Spain (5) · France (4) · Australia (3) · Poland (3) · Switzerland (3) · Argentina (2) · Austria (2) · Belgium (2) · Bulgaria (2) · Malaysia (2)
Carlos A Zarate, M.D. (3) · Brandon Bentzley, MD (2) · Jessica Harder, MD (2) · Maurizio Fava, MD (2) · BioXcel MM, MD (1) · Caleb M Adler, MD (1) · Chad D Rethorst, Ph.D. (1) · Christopher J Pittenger, MD,PhD (1) · Colleen Loo, FRANZCP; MD (1) · Craig Erickson, MD (1) · Daniel F Kripke, MD (1) · David Abramson, MD (1)
PMID 16630205, PMID 18671864, PMID 20074703, PMID 21199966, PMID 23364679, PMID 25328711, PMID 27366831, PMID 28044255, PMID 30184133, PMID 34787653, PMID 34798853, PMID 36375174, PMID 40779267, PMID 42234079, PMID 42247279
2014 (1), 2016 (1), 271201100006I-0-27100007-1 (1), R01MH125160 (1), R21DA029295 (1), R42MH123357 (1), U10CA081920 (1)